Associated factors from all patients with high risk neuroblastoma including patient’s age, sex, grade of tumor differentiation, MYCN status, Shimada histology, serum NSE, urine VMA and type of health care system were analyzed to determine predictive factors of treatment response after topotecan and cyclophosphamide containing induction regimen. Here, MYCN is linked to neuroblastoma.